admin – Page 3905 – Get News Story

Pancreatic Ductal Adenocarcinoma Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Pancreatic Ductal Adenocarcinoma pipeline constitutes 80+ key companies continuously working towards developing 80+ Pancreatic Ductal Adenocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic Ductal Adenocarcinoma Market.

The Pancreatic Ductal Adenocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report:

Companies across the globe are diligently working toward developing novel Pancreatic Ductal Adenocarcinoma treatment therapies with a considerable amount of success over the years.
Pancreatic Ductal Adenocarcinoma companies working in the treatment market are Deciphera Pharmaceuticals, Revolution Medicines, Syntrix Biosystems, Amplia Therapeutics, ZielBio, Cend Therapeutics Inc, Cardiff Oncology, Eucure Biopharma, Jiangsu Alphamab Biopharmaceuticals, and others, are developing therapies for the Pancreatic Ductal Adenocarcinoma treatment

Emerging Pancreatic Ductal Adenocarcinoma therapies in the different phases of clinical trials are- DCC-3116, RMC-6236, SX-682, AMP 945, ZB131, CEND-1, Onvansertib, YH003, KN046, and others are expected to have a significant impact on the Pancreatic Ductal Adenocarcinoma market in the coming years.
In January 2025, Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative treatments for advanced solid tumors and serious diseases, along with WARPNINE Incorporated, Western Australia’s first not-for-profit clinical research organization specializing in pancreatic, gastrointestinal, and rare cancers, has announced promising preliminary results from the Phase 1b/2a iLSTA trial (ACTRN12623000223639). The trial evaluates certepetide (formerly LSTA1), Lisata’s proprietary investigational iRGD cyclic peptide, in combination with standard-of-care chemotherapy and immunotherapy as a first-line treatment for locally advanced, non-resectable pancreatic ductal adenocarcinoma (PDAC).
In October 2024, Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced that the first patient has been dosed in RASolute 302, a Phase 3 registrational trial evaluating RMC-6236, a RAS(ON) multi-selective inhibitor, for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
In May 2024, Hong Kong-based biopharmaceutical company Hutchmed has initiated a Phase II/III clinical trial in China to evaluate surufatinib in combination with other drugs as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). The treatment regimen includes surufatinib, camrelizumab from Jiangsu Hengrui Pharmaceuticals, nab-paclitaxel, and gemcitabine.
In January 2024, Jacobio Pharmaceuticals’ pancreatic cancer candidate, glecirasib, has demonstrated improved safety and efficacy compared to previous studies in a Phase I/II trial involving patients with pancreatic cancer and other solid tumors. The Phase I/II monotherapy global study of glecirasib reported a confirmed objective response rate (cORR) of 48% and a disease control rate (DCR) of 90%. These study results will support the submission of a new drug application (NDA) for pancreatic cancer.

Pancreatic Ductal Adenocarcinoma Overview

Due to delayed diagnosis and a poor prognosis, pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive, fatal cancer. More than 90% of cases of pancreatic cancer are caused by this form of tumor, which is the most common type and develops in the exocrine compartment.

Get a Free Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight

Emerging Pancreatic Ductal Adenocarcinoma Drugs Under Different Phases of Clinical Development Include:

DCC-3116: Deciphera Pharmaceuticals
RMC-6236: Revolution Medicines
SX-682: Syntrix Biosystems
AMP 945: Amplia Therapeutics
ZB131: ZielBio
CEND-1: Cend Therapeutics Inc
Onvansertib: Cardiff Oncology
YH003: Eucure Biopharma
KN046: Jiangsu Alphamab Biopharmaceuticals

Pancreatic Ductal Adenocarcinoma Route of Administration

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Intravenous
Subcutaneous

Pancreatic Ductal Adenocarcinoma Molecule Type

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types, such as

Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics Assessment

Pancreatic Ductal Adenocarcinoma Assessment by Product Type
Pancreatic Ductal Adenocarcinoma By Stage and Product Type
Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
Pancreatic Ductal Adenocarcinoma By Stage and Route of Administration
Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type
Pancreatic Ductal Adenocarcinoma by Stage and Molecule Type

DelveInsight’s Pancreatic Ductal Adenocarcinoma Report covers around 80+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Pancreatic Ductal Adenocarcinoma product details are provided in the report. Download the Pancreatic Ductal Adenocarcinoma pipeline report to learn more about the emerging Pancreatic Ductal Adenocarcinoma therapies

Some of the key companies in the Pancreatic Ductal Adenocarcinoma Therapeutics Market include:

Key companies developing therapies for Pancreatic Ductal Adenocarcinoma are – Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.

Pancreatic Ductal Adenocarcinoma Pipeline Analysis:

The Pancreatic Ductal Adenocarcinoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Ductal Adenocarcinoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Ductal Adenocarcinoma Treatment.
Pancreatic Ductal Adenocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Pancreatic Ductal Adenocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Ductal Adenocarcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma drugs and therapies

Pancreatic Ductal Adenocarcinoma Pipeline Market Drivers

Increasing pervasiveness of the disease, increasing demand of targeted therapy are some of the important factors that are fueling the Pancreatic Ductal Adenocarcinoma Market.

Pancreatic Ductal Adenocarcinoma Pipeline Market Barriers

However, lack of early diagnostic markers, complicated and multifactorial nature of disease, diverse genetics and rapid metastasis and other factors are creating obstacles in the Pancreatic Ductal Adenocarcinoma Market growth.

Scope of Pancreatic Ductal Adenocarcinoma Pipeline Drug Insight

Coverage: Global
Key Pancreatic Ductal Adenocarcinoma Companies: Deciphera Pharmaceuticals, Revolution Medicines, Syntrix Biosystems, Amplia Therapeutics, ZielBio, Cend Therapeutics Inc, Cardiff Oncology, Eucure Biopharma, Jiangsu Alphamab Biopharmaceuticals, and others
Key Pancreatic Ductal Adenocarcinoma Therapies: DCC-3116, RMC-6236, SX-682, AMP 945, ZB131, CEND-1, Onvansertib, YH003, KN046, and others
Pancreatic Ductal Adenocarcinoma Therapeutic Assessment: Pancreatic Ductal Adenocarcinoma current marketed and Pancreatic Ductal Adenocarcinoma emerging therapies
Pancreatic Ductal Adenocarcinoma Market Dynamics: Pancreatic Ductal Adenocarcinoma market drivers and Pancreatic Ductal Adenocarcinoma market barriers

Request for Sample PDF Report for Pancreatic Ductal Adenocarcinoma Pipeline Assessment and clinical trials

Table of Contents

1. Pancreatic Ductal Adenocarcinoma Report Introduction

2. Pancreatic Ductal Adenocarcinoma Executive Summary

3. Pancreatic Ductal Adenocarcinoma Overview

4. Pancreatic Ductal Adenocarcinoma- Analytical Perspective In-depth Commercial Assessment

5. Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics

6. Pancreatic Ductal Adenocarcinoma Late Stage Products (Phase II/III)

7. Pancreatic Ductal Adenocarcinoma Mid Stage Products (Phase II)

8. Pancreatic Ductal Adenocarcinoma Early Stage Products (Phase I)

9. Pancreatic Ductal Adenocarcinoma Preclinical Stage Products

10. Pancreatic Ductal Adenocarcinoma Therapeutics Assessment

11. Pancreatic Ductal Adenocarcinoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pancreatic Ductal Adenocarcinoma Key Companies

14. Pancreatic Ductal Adenocarcinoma Key Products

15. Pancreatic Ductal Adenocarcinoma Unmet Needs

16 . Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers

17. Pancreatic Ductal Adenocarcinoma Future Perspectives and Conclusion

18. Pancreatic Ductal Adenocarcinoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pancreatic Ductal Adenocarcinoma Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics

Magic Glass Prescott Celebrates 500 Google Reviews as a Trusted Windshield Replacement Provider

Magic Glass Prescott Logo

Magic Glass Prescott just passed 500 reviews on google. Magic Glass Prescott has been providing quality service to the Prescott, Arizona area for over 2 decades.

Prescott, AZ – March 07, 2025 – Magic Glass Prescott, a leader in windshield replacement and auto glass services, is celebrating a significant milestone—500 Google reviews from satisfied customers. Since 2001, the company has provided expert windshield replacement to drivers in Prescott, Prescott Valley, and Chino Valley, earning a reputation for quality workmanship and outstanding customer service.

For more than two decades, Magic Glass Prescott has helped vehicle owners replace damaged windshields quickly and safely. Whether due to rock chips, cracks, or extensive damage, drivers in the Prescott area trust the company for professional windshield replacement that meets industry safety standards.

“We are incredibly grateful to our customers for their trust and support,” said Daniel Keller, owner of Magic Glass Prescott. “Reaching 500 Google reviews reflects our dedication to providing high-quality windshield replacement and ensuring every customer leaves satisfied.”

Quality Workmanship and Hassle-Free Service

Magic Glass Prescott uses premium materials and expert technicians to ensure every windshield replacement is done correctly. With mobile service available, customers can have their windshields replaced at home, work, or a preferred location. The company also assists with insurance claims, making the process as smooth as possible.

Over 20 Years of Trusted Service

Since 2001, Magic Glass Prescott has been the go-to choice for windshield replacement in Prescott, Prescott Valley, and Chino Valley. The milestone of 500 Google reviews highlights the trust and satisfaction of customers who rely on the company for safe, reliable, and affordable service.

For professional windshield replacement from a top-rated local provider, contact Magic Glass Prescott today.

Media Contact
Company Name: Magic Glass Prescott
Contact Person: Daniel Keller
Email: Send Email
Phone: (928) 541-0101
Address:720 6th St
City: Prescott
State: Arizona
Country: United States
Website: www.magicglassprescott.com

Historian C.Q. Turnstone to Release Debut Novel Avarice of Empire

Independent UK publishing house Brindle Books Ltd is pleased to announce its latest release: ‘Avarice of Empire’ by Exeter-based historian C.Q. Turnstone. The book is the culmination of many years of research and tells the previously untold true story of Captain Charles Agnew, a cavalry officer with the ‘Scarlet Lancers’, who died ‘by the hand of an assassin’ in Egypt on 22nd March 1873.

Turnstone, a postgraduate historian at the University of Exeter, has been fascinated by Agnew’s story since he first saw a memorial to the fallen officer inside Canterbury Cathedral on a rainy Sunday in May 2015. At that moment, says the author, “my imagination was captured instantly. Over time, I began to research what happened, and the more I discovered, the more I knew that this was a story I needed to tell.”

‘Avarice of Empire’ is a work of historical fiction that tells a story about real people and events with as much historical accuracy as possible. As well as Charles Agnew, it’s about the fortitude of Victorian women, class division and colonial prejudice, early photography and the embryonic intelligence service, a revolution in global communications, and how an Irishman discovered what would become India’s largest gold mine.

Avarice of Empire by C.Q. Turnstone is released on 6th March 2025 by Brindle Books Ltd in paperback (ISBN 978-1-915631-23-7) and e-book formats.

For further details and buying options, please visit the following link: https://www.amazon.co.uk/Avarice-Empire-C-Q-Turnstone-ebook/dp/B0DTXK915R

Visit: https://www.brindlebooks.co.uk

Media Contact
Company Name: Brindle Books Ltd
Contact Person: Richard Hinchliffe
Email: Send Email
Country: United Kingdom
Website: https://www.brindlebooks.co.uk/

Lafayette Landscaping Pros Launches New Website and Joins Cajun Country Lawn Care

Lafayette, LA – March 07, 2025 – Lafayette Landscaping Pros, a trusted name in professional landscaping and lawn care services, is excited to announce the launch of its brand-new website, providing customers with an easier way to explore services and request quotes online. In addition to this milestone, Lafayette Landscaping Pros has officially been acquired by Cajun Country Lawn Care, a leader in landscaping in Lafayette, LA, known for its commitment to excellence and customer satisfaction.

The new website aims to enhance customer experience by offering detailed service descriptions, an intuitive contact form, and helpful landscaping tips. Whether homeowners need routine lawn care in Lafayette, LA, expert landscape design, or seasonal maintenance, the updated platform ensures a seamless way to connect with professionals who can bring their outdoor vision to life.

“We are thrilled about this new chapter for Lafayette Landscaping Pros and our partnership with Cajun Country Lawn Care,” said the owner of Cajun Country Lawn Care. “With our combined expertise and dedication to quality service, we’re expanding our reach and ability to provide top-tier landscaping in Lafayette, LA to even more residents and businesses.”

Through this acquisition, Lafayette Landscaping Pros customers will now benefit from a wider range of services, including premium lawn maintenance in Lafayette, LA, professional irrigation solutions, tree and shrub care, and customized landscape enhancements. Cajun Country Lawn Care has built a reputation for reliability and superior service, ensuring that existing and new customers receive the highest standard of lawn and landscape care.

“We understand how important a well-maintained lawn and landscape are to our customers, and we are committed to delivering the best possible results,” added the spokesperson. “With the launch of the new website and our expanded capabilities, we look forward to continuing to serve Lafayette and the surrounding areas with exceptional lawn care in Lafayette, LA.”

Customers can now visit the newly launched website to schedule consultations, browse service offerings, and receive expert insights on maintaining a healthy, beautiful landscape year-round. The integration with Cajun Country Lawn Care also means access to more resources, experienced landscaping professionals, and enhanced customer support.

For more information about Lafayette Landscaping Pros and the new website launch, or to learn about the expanded services now available through Cajun Country Lawn Care, visit https://lafayettelandscapingpros.com/ or call (337) 282-9208.

About Lafayette Landscaping

ProsLafayette Landscaping Pros is a professional landscaping and lawn care company serving Lafayette, LA, and surrounding areas. Specializing in landscape design, lawn maintenance, and seasonal care, the company has built a reputation for high-quality service and customer satisfaction.

About Cajun Country Lawn Care

Cajun Country Lawn Care is a leading landscaping company in Lafayette, LA, providing expert lawn care, landscape maintenance, and outdoor solutions. With years of experience and a dedication to excellence, the company continues to enhance outdoor spaces throughout the region.

Media Contact
Company Name: Lafayette Landscaping Pros
Contact Person: Colby Fitch
Email: Send Email
Phone: (337) 282-9208
Address:507 Herbert Road
City: Lafayette
State: Louisiana 70506
Country: United States
Website: www.lafayettelandscapingpros.com/

Displacement by J. Thomas Hunton: A New Release in Science Fiction Explores Humanity’s Cosmic Destiny

Florida, Tampa – Displacement, the debut science fiction novel by J. Thomas Hunton, has captured the interest of readers since its release on October 15, 2024. The novel follows astronaut Georgia Evans and her crew as they embark on a mission aboard the deep-space spacecraft Asteria. The story delves into humanity’s place in the universe and raises philosophical questions about the relationship between technological progress and human vulnerability.

In Displacement, an anomaly in deep space sends the crew of the Asteria on a quest to understand the mysterious force at the heart of the disturbance. As they encounter “the darkness,” an ancient cosmic entity, the crew is forced to confront ethical challenges that test their understanding of the universe. Themes of accountability, space-time manipulation, and survival are woven into the narrative, presenting readers with a complex portrayal of human ingenuity in the face of an unknown threat.

The novel is available in three formats: Kindle (available instantly), Hardcover, and Paperback. With the ISBN-13 of 979-8895694084, Displacement continues to draw attention in the science fiction genre for its unique approach to the genre’s conventions. By combining action with introspective questions, the story invites readers to reflect on humanity’s ability to adapt and survive in an increasingly complex and uncertain universe.

The book has been met with positive feedback, as reflected in its strong ratings on Amazon. Its thoughtful exploration of contemporary science fiction themes, particularly the intersection of human progress and the unknown, has resonated with readers. Displacement continues to engage a growing audience by providing an immersive narrative that challenges the boundaries of both the genre and the questions it raises.

For more information about Displacement or to purchase the book, visit its page on Amazon.

Displacement is also available in audiobook format on Storytel

DISCLAIMER: This press release is for informational purposes only. It does not constitute professional advice, nor should it be relied upon for any decision-making. While the information herein is believed to be accurate, it is not guaranteed. J. Thomas Hunton and associated parties are not liable for any inaccuracies. Any actions taken based on this press release are at the reader’s discretion.

This press release aims to update readers on the continued availability and reception of J. Thomas Hunton’s Displacement. It serves to inform the public about the book’s availability across various formats and the ongoing discussion surrounding its themes of space exploration and human ethical challenges.

J. Thomas Hunton is a science fiction author who explores the intersection of technology, humanity, and existential questions.

For media inquiries, interviews, or more information about Displacement, please contact:

Email: jthomashunton@gmail.com

For additional details about J. Thomas Hunton and Displacement, visit: https://jthomashunton1.com/

Media Contact
Company Name: Displacement
Contact Person: Jeffrey Hunton
Email: Send Email
Phone: 8133521470
City: Tampa
State: Florida
Country: United States
Website: https://jthomashunton1.com/

Bryan Harr’s The Prepared Heart Gains Strong Reader Response Amid Rising Demand for Essential Faith-Based Literature

Faith-Based Book Garners Praise for Its Practical Approach to Spiritual Growth and Biblical Teachings.

Columbia, Illinois – March 7, 2025 – Bryan Harr’s The Prepared Heart presents a structured approach for readers to engage with their spiritual journey. The Christian faith genre remains a widely popular category each year, drawing a variety of authors and perspectives. Writing within this genre requires thorough research to resonate with its audience and reflect meaningful teachings. The Prepared Heart offers practices to help individuals explore their relationship with God, suitable for both those new to their faith and those with long-standing religious experience. The book integrates biblical references with essential examples, detailing steps and narrative elements that demonstrate the application of scriptural teachings in daily life.

Image of Bryan Harr

Since its release on October 21, 2024, The Prepared Heart has maintained a 4.9 rating on Amazon, reflecting a strong reader response. This reception aligns with a broader industry trend where books that combine traditional religious teachings with essential guidance are seeing increased interest. Market insights suggest that readers are seeking books that provide actionable spiritual direction for contemporary challenges. The book has been noted by various faith-based communities for its accessible approach to biblical principles, though some may question its place among other resources in the field. It has also attracted attention from those seeking materials that help integrate faith into everyday living.

Bryan Harr draws on both biblical texts and personal experience to offer insights on integrating spiritual practices into daily life. While some may question whether traditional religious teachings can be effectively adapted for modern readers, his work contributes to ongoing discussions in the faith-based publishing sector about making these teachings relevant and approachable for today’s audience.

The Prepared Heart is available for purchase on Amazon, with the ISBN-13: 979-8343972832.

DISCLAIMER: This press release, distributed by Bryan Harr’s team, is for informational purposes only. It does not constitute investment, legal, or fiscal advice, nor should it be relied upon for business decisions. While the information herein is believed to be accurate, it is not guaranteed. Bryan Harr, his team, and associated parties are not liable for any inaccuracies. Any actions taken based on this press release are at the reader’s discretion.

Purpose of the Press Release

This press release announces Bryan Harr’s new book, The Prepared Heart. The release outlines the book’s examination of preparing one’s heart to seek God and aims to raise awareness about spiritual growth and faith-driven living. It seeks to inform potential readers and media outlets about the book’s content and Harr’s objective to support individuals on their spiritual journeys.

For more information about The Prepared Heart, please contact below.

Media Contact
Company Name: The Prepared Heart
Contact Person: Bryan Harr
Email: Send Email
City: Columbia
State: Illinois
Country: United States
Website: https://bryanharrauthor.com/

Cell And Gene Therapy For Multiple Myeloma Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron

The Key Cell And Gene Therapy For Multiple Myeloma Companies in the marlket include – Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others

The Cell And Gene Therapy For Multiple Myeloma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cell And Gene Therapy For Multiple Myeloma pipeline products will significantly revolutionize the Cell And Gene Therapy For Multiple Myeloma market dynamics.

DelveInsight’s “Cell And Gene Therapy For Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cell And Gene Therapy For Multiple Myeloma, historical and forecasted epidemiology as well as the Cell And Gene Therapy For Multiple Myeloma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cell And Gene Therapy For Multiple Myeloma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cell And Gene Therapy For Multiple Myeloma Market Forecast

Some of the key facts of the Cell And Gene Therapy For Multiple Myeloma Market Report:

The Cell And Gene Therapy For Multiple Myeloma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In September 2024, Bristol Myers Squibb (BMS) and 2seventy bio have decided to halt enrollment in the Phase III KarMMa-9 clinical trial of Abecma (idecabtagene vicleucel) for newly diagnosed multiple myeloma (NDMM) patients. The study was designed to assess Abecma combined with lenalidomide maintenance compared to lenalidomide maintenance alone following an autologous stem cell transplant in NDMM patients with a suboptimal response.
In July 2024, Pfizer halted the Phase III CIFFREO trial assessing the investigational gene therapy fordadistrogene movaparvovec. Previously, the therapy failed to meet the primary objective of improving motor function in boys aged 4 to 7 years compared to a placebo.
In July 2024, Miltenyi Biotec signed a Letter of Intent with the Translational Health Science and Technology Institute (THSTI). This collaboration seeks to advance the development of innovative cell and gene therapies to meet the increasing demand for groundbreaking cancer treatments.
In May 2024, Taysha Gene Therapies was granted a Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA) for its gene therapy candidate, TSHA-102, aimed at treating Rett syndrome.
In April 2024, Charles River Laboratories International, Inc. has entered into a plasmid DNA contract development and manufacturing (CDMO) partnership with Axovia Therapeutics Ltd. Under this collaboration, Charles River will produce High Quality (HQ) gene of interest plasmid to aid in the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a rare condition with limited treatment options and no known cure.
In April 2024, Ginkgo Bioworks has successfully concluded its gene therapy collaboration with Biogen, which began in May 2021. The partnership focused on improving the industry standards for producing recombinant adeno-associated virus (AAV)-based vectors. The collaboration successfully enhanced AAV production titers in Biogen’s gene therapy manufacturing processes, achieving its intended goals.
In March 2024, Johnson & Johnson announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recommended CARVYKTI for treating adult patients with Relapsed/Refractory Cell And Gene Therapy For Multiple Myeloma (RRMM) who have undergone at least one prior therapy, including a proteasome inhibitor and an IMiD, and are refractory to lenalidomide.
Key Cell And Gene Therapy For Multiple Myeloma Companies: Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others
Key Cell And Gene Therapy For Multiple Myeloma Therapies: CARVYKTI (ciltacabtagene autoleucel), Mezigdomide (CC-92480), Linvoseltamab (REGN5458), Venetoclax, ABBV 383, Talquetamab, Linvoseltamab, Descartes 08, Lenalidomide, Selinexor, Descartes-25, Pomalidomide, TG01, Cyclophosphamide, AZD0305, bb2121, EOS884448, Elranatamab, APG-2575, TNB-383B, PHE885, and others
The Cell And Gene Therapy For Multiple Myeloma epidemiology based on gender analyzed that males are affected more in case of Cell And Gene Therapy For Multiple Myeloma as compared to females.
The Cell And Gene Therapy For Multiple Myeloma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cell And Gene Therapy For Multiple Myeloma pipeline products will significantly revolutionize the Cell And Gene Therapy For Multiple Myeloma market dynamics.

Cell And Gene Therapy For Multiple Myeloma Overview

Cell and gene therapy is an advanced treatment approach for Multiple Myeloma (MM) that harnesses the power of genetic modifications and immune cells to target and destroy cancerous plasma cells. This therapy includes Chimeric Antigen Receptor T-cell (CAR-T) therapy, where a patient’s T-cells are engineered to recognize and attack BCMA (B-cell maturation antigen)-expressing myeloma cells.

Approved CAR-T therapies, such as Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel), have shown remarkable efficacy in relapsed/refractory MM cases. Other investigational gene-modified therapies, including T-cell receptor (TCR) therapies and CRISPR-based gene edits, are under development.

Get a Free sample for the Cell And Gene Therapy For Multiple Myeloma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market

Cell And Gene Therapy For Multiple Myeloma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cell And Gene Therapy For Multiple Myeloma Epidemiology Segmentation:

The Cell And Gene Therapy For Multiple Myeloma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Cell And Gene Therapy For Multiple Myeloma
Prevalent Cases of Cell And Gene Therapy For Multiple Myeloma by severity
Gender-specific Prevalence of Cell And Gene Therapy For Multiple Myeloma
Diagnosed Cases of Episodic and Chronic Cell And Gene Therapy For Multiple Myeloma

Download the report to understand which factors are driving Cell And Gene Therapy For Multiple Myeloma epidemiology trends @ Cell And Gene Therapy For Multiple Myeloma Epidemiology Forecast

Cell And Gene Therapy For Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cell And Gene Therapy For Multiple Myeloma market or expected to get launched during the study period. The analysis covers Cell And Gene Therapy For Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cell And Gene Therapy For Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cell And Gene Therapy For Multiple Myeloma Therapies and Key Companies

CARVYKTI (ciltacabtagene autoleucel): Johnson & Johnson Innovative Medicine
Mezigdomide (CC-92480): Bristol Myers Squibb
Linvoseltamab (REGN5458): Regeneron
Venetoclax: AbbVie and Roche
ABBV 383: AbbVie
Talquetamab: Janssen Pharmaceutical
Linvoseltamab: Regeneron Pharmaceuticals
Descartes 08: Cartesian Therapeutics
Lenalidomide: Alliance Foundation Trials, LLC.
Selinexor: US Oncology Research
Descartes-25: Cartesian Therapeutics
Pomalidomide: GlaxoSmithKline
TG01: Targovax ASA
Cyclophosphamide: Janssen Research & Development
AZD0305: AstraZeneca
bb2121: Celgene
EOS884448: Bristol-Myers Squibb
Elranatamab: Pfizer
APG-2575: Ascentage Pharma Group Inc.
TNB-383B: TeneoOne Inc.
PHE885: Novartis

Discover more about therapies set to grab major Cell And Gene Therapy For Multiple Myeloma market share @ Cell And Gene Therapy For Multiple Myeloma Treatment Landscape

Cell And Gene Therapy For Multiple Myeloma Market Strengths

Emerging therapies such as CAR-T cell and monoclonal antibodies showing promising results in treating multiple myeloma patients and expected to drive the growth of market. It also amends the treatment landscape in cancer due to its high specificity and minimal side effect profile.

Cell And Gene Therapy For Multiple Myeloma Market Opportunities

BCMA-targeting therapies are expected to result in noteworthy revenues due to premium pricing and clinical benefit in heavily pretreated patients.

Scope of the Cell And Gene Therapy For Multiple Myeloma Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Cell And Gene Therapy For Multiple Myeloma Companies: Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others
Key Cell And Gene Therapy For Multiple Myeloma Therapies: CARVYKTI (ciltacabtagene autoleucel), Mezigdomide (CC-92480), Linvoseltamab (REGN5458), Venetoclax, ABBV 383, Talquetamab, Linvoseltamab, Descartes 08, Lenalidomide, Selinexor, Descartes-25, Pomalidomide, TG01, Cyclophosphamide, AZD0305, bb2121, EOS884448, Elranatamab, APG-2575, TNB-383B, PHE885, and others
Cell And Gene Therapy For Multiple Myeloma Therapeutic Assessment: Cell And Gene Therapy For Multiple Myeloma current marketed and Cell And Gene Therapy For Multiple Myeloma emerging therapies
Cell And Gene Therapy For Multiple Myeloma Market Dynamics: Cell And Gene Therapy For Multiple Myeloma market drivers and Cell And Gene Therapy For Multiple Myeloma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Cell And Gene Therapy For Multiple Myeloma Unmet Needs, KOL’s views, Analyst’s views, Cell And Gene Therapy For Multiple Myeloma Market Access and Reimbursement

To know more about Cell And Gene Therapy For Multiple Myeloma companies working in the treatment market, visit @ Cell And Gene Therapy For Multiple Myeloma Clinical Trials and Therapeutic Assessment

Table of Contents

1. Cell And Gene Therapy For Multiple Myeloma Market Report Introduction

2. Executive Summary for Cell And Gene Therapy For Multiple Myeloma

3. SWOT analysis of Cell And Gene Therapy For Multiple Myeloma

4. Cell And Gene Therapy For Multiple Myeloma Patient Share (%) Overview at a Glance

5. Cell And Gene Therapy For Multiple Myeloma Market Overview at a Glance

6. Cell And Gene Therapy For Multiple Myeloma Disease Background and Overview

7. Cell And Gene Therapy For Multiple Myeloma Epidemiology and Patient Population

8. Country-Specific Patient Population of Cell And Gene Therapy For Multiple Myeloma

9. Cell And Gene Therapy For Multiple Myeloma Current Treatment and Medical Practices

10. Cell And Gene Therapy For Multiple Myeloma Unmet Needs

11. Cell And Gene Therapy For Multiple Myeloma Emerging Therapies

12. Cell And Gene Therapy For Multiple Myeloma Market Outlook

13. Country-Wise Cell And Gene Therapy For Multiple Myeloma Market Analysis (2019–2032)

14. Cell And Gene Therapy For Multiple Myeloma Market Access and Reimbursement of Therapies

15. Cell And Gene Therapy For Multiple Myeloma Market Drivers

16. Cell And Gene Therapy For Multiple Myeloma Market Barriers

17. Cell And Gene Therapy For Multiple Myeloma Appendix

18. Cell And Gene Therapy For Multiple Myeloma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cell And Gene Therapy For Multiple Myeloma Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron

Zipline Ski Unveils Revolutionary Hexagon Triax Weave Graphite Technology for Unparalleled Performance

Innovative Ski Pole Design Co-Created by Olympic Champion Alex Ferreira

Baltimore, MD – March 07, 2025 – Zipline Ski, a leader in high-performance ski equipment, is redefining the standards of ski pole innovation with the launch of its Hexagon Triax Weave Graphite Technology. Developed in collaboration with Olympic, World Cup, and X Games Champion Alex Ferreira, this advanced engineering breakthrough offers enhanced strength, reduced weight, and superior vibration dampening, catering to skiers at every level—from recreational enthusiasts to elite competitors.

Skier: Dan Herby at Chatter Creek , British Columbia. Photo Credit Freeride Media

A Breakthrough in Ski Pole Engineering

Unlike traditional round ski poles, Zipline Ski’s latest offering introduces a hexagonal shaft design. Dupont’s Kevlar-reinforced construction further enhances durability while keeping the poles lightweight, a crucial factor for performance-driven skiers who demand precision and reliability. Its signature “trigger finger” ZipGrip is built with thermoplastic (TPU) and contours to your hand, preventing your gloves from slipping. Velcro Straps are easily adjustable on the fly. Also, it has tough and sharp carbide Zip Tip with teeth, allowing precise pole plants and secured grip in any condition.

“As leaders in ski technology, we are committed to enhancing the performance and experience of skiers at every level,” said Chuck Heidenreich, President of Zipline Ski. “Our Hexagon Triax Weave Graphite poles offer the strength, lightweight feel, and responsiveness that athletes need to perform at their best. By working alongside a champion like Alex Ferreira, we’ve designed a ski pole that meets the highest standards of performance and durability.”

Trusted by the World’s Top Skiers

Zipline Ski’s commitment to cutting-edge technology has made its products the go-to choice for Olympic athletes and competitive skiers worldwide. The Alex Ferreira Hex 16K Graphite Kevlar Hybrid ski poles—specifically designed with Ferreira’s input—played a pivotal role in his dominant the 2024 and 2025 FIS Crystal Globe-winning season.

Several other world-class athletes trust Zipline Ski’s high-performance ski poles, including:

David Wise – Two-time Olympic medalist (Gold in 2018, Silver in 2022) and three-time X Games halfpipe champion, who uses the MR DW Blurr David Wise autograph edition graphite ski pole.
Ben Harrington – New Zealand’s representative in the 2022 Winter Olympics in halfpipe skiing uses the Zipline Blurr model.
U.S. Ski Team Mogul Athletes, including Charlie Mickel, Dylan Marcellini, and Nash Lucas, rely on Zipline ski poles and/or goggles for competition.

A Decade of Excellence in Ski Equipment Innovation

Zipline Ski was founded by former World Cup freestyle skiers and coaches, with the mission of delivering elite-quality ski equipment to athletes and enthusiasts alike. Over the past decade, the brand has grown into an industry leader, recognized for its expert craftsmanship and continuous technological advancements.

A standout feature of Zipline Ski poles is their high-modulus carbon fiber graphite construction, which significantly reduces weight while improving durability and vibration absorption. These attributes make them ideal for competitive skiers seeking gear that enhances performance and minimizes fatigue on the slopes.

“Performance skiing demands equipment that is as tough as the athletes using it,” said Heidenreich. “Our design team, made up of skiers who understand the sport at the highest level, continues to innovate and refine our technology to ensure we stay ahead of the curve.”

Beyond ski poles, Zipline Ski offers a range of high-performance ski gear, including ski goggles, snowboard goggles, ski bags, and freestyle mogul skis, all designed with the same commitment to quality and performance.

Why the Hexagon Shape Matters

A hexagon is generally considered stronger than a round shape, like a circle, because it distributes forces more evenly across its sides. This makes a hexagon better at handling pressure, while a circle, with just one curved edge, has to distribute force less effectively.

Here are some key points about the strength of hexagons:

Even force distribution: With multiple sides, a hexagon spreads weight evenly, making it more resistant to deformation.
Nature’s design: Bees build honeycombs with hexagonal cells, showing how nature uses this shape for strength and efficiency.
Compared to a circle: Although circles are strong because they have no corners, a hexagon is typically stronger when comparing shapes with the same perimeter.

The Hexagon Triax Weave Graphite Technology is more than just a structural change—it represents an evolution in ski pole design. Traditional round poles, while effective, do not optimize aerodynamics or power distribution as efficiently as a hexagonal structure. By utilizing this shape, Zipline Ski has improved:

“ZIP TOUCH” DUAL DENSITY GRIP – Our signature “trigger finger” ZipGrip is built with thermoplastic (TPU) and contours to your hand, preventing your gloves from slipping.
Aerodynamics – Reduced air resistance allows for smoother, more controlled movements at high speeds.
Power Transfer – The unique structure maximizes force distribution, ensuring better energy efficiency with each turn and push.

Designed for Skiers of All Levels

While the Hexagon Triax Weave Graphite ski poles were engineered with input from elite athletes, their benefits extend to skiers at all experience levels. Whether navigating steep backcountry terrain, carving through fresh powder, or training for competitive events, these ski poles provide a tangible edge in performance.

From recreational skiers looking to upgrade their gear to seasoned professionals preparing for competition, Zipline Ski’s newest innovation is designed to elevate the skiing experience for all.

The Hexagon Triax Weave Graphite ski poles are now available for purchase exclusively through Zipline Ski’s official website (www.ziplineski.com). With the ski season winding down starting March 1st, now is the time for skiers to invest in the latest advancements in ski technology.

About Zipline Ski

Zipline Ski is a premier manufacturer of high-performance ski equipment, specializing in ski poles, goggles, ski bags, and freestyle mogul skis. Founded by former World Cup freestyle skiers and coaches, the company has spent the last decade refining cutting-edge technology to enhance ski performance. Trusted by Olympians, professionals, and passionate skiers worldwide, Zipline Ski continues to set new standards in the ski equipment industry.

Alex Ferreira winning the FIS Crystal Globe for the second time since switching to the Alex Ferreira Autograph Model Zipline Kex16K ski poles. Photo Credit: FIS

Media Contact
Company Name: Zipline Ski
Contact Person: Chuck Heidenreich
Email: Send Email
Country: United States
Website: https://www.ziplineski.com/

Amiblu supports UNESCO World Engineering Day 2025 campaign

WED is jointly operated by UNESCO and the World Federation for Engineering Organizations (WFEO), which spans some 100 countries and represents more than 30 million engineers, and is an International Day proclaimed by the UNESCO General Conference and open to everyone.

London, UK – 7 Mar, 2025 – Amiblu, as a leading manufacturer of glass fibre reinforced plastic (GRP) pipes, has been selected as an official partner for UNESCO World Engineering Day for Sustainable Development (WED) 2025, which was launched at UNESCO Headquarters in Paris on 4 March 2025.

The launch in March marks the start of a year-long campaign of events, films and related articles and news, highlighting the achievements of engineers and engineering around the world, and promoting engineering as a career. The WED campaign has an estimated global reach of more than 100 million individuals, and this year’s theme of “Shaping our sustainable future through engineering” focuses on the essential role that engineering has to play in achieving the UN’s 17 Sustainable Development Goals (SDGs).

Produced by the SJH Group – the official media partner and broadcaster for WED – all campaign content, which includes a multimedia hub dedicated to Amiblu, is hosted on the WED website at www.worldengineeringday.net.

As an official partner, Amiblu’s insights and expertise will form an integral part of the 12-month campaign, which provides a springboard for governments, UN-associated organisations, policymakers, educators and leaders in the public and private sectors to raise awareness of the importance of engineering. Amiblu has been at the forefront of developing durable, reliable solutions for water and energy infrastructure for many decades. The latest achievement is a low-carbon GRP pipe that can significantly reduce CO2 emissions across water and energy infrastructure projects, which are responsible for a major share of global emissions.

“At Amiblu, we are driven by a purpose to build sustainable water infrastructure that serves generations,” says Wolfgang Stangassinger, CEO of Amiblu. “Our pipes help reduce water loss, lower emissions, and extend the lifetime of critical water infrastructure. This way, we ensure that cities and communities are resilient in the face of climate change. We don’t just make pipes, we create solutions that secure water, protect the environment, and make infrastructure smarter and more sustainable.”

Addressing the significance of WED, Mustafa Shehu, President of the WFEO, says: “World Engineering Day 2025 is all about putting engineering in the global spotlight, showing how engineers are leading the way in the effort to meet the UN’s Sustainable Development Goal targets, and inspiring the next generation to find out more about what a career in engineering has to offer.”

Jacques de Mereuil, Executive Director of the WFEO, says: “We’re thrilled to be involved in launching this important international celebration and campaign at UNESCO’s global headquarters in Paris, and delighted to have Amiblu involved, as an authority in the glass-fibre reinforced plastic pipes industry.”

To view Amiblu’s WED content, go to https://worldengineeringday.net/partner-stories/amiblu/.

Notes to editor:

The WED 2025 launch, campaign and related content are live on www.worldengineeringday.net.

For further information about WED 2025 please email publishing@stjamess.org.

For further information about Amiblu, please visit: https://www.amiblu.com

Media Contact
Company Name: St James’s House
Contact Person: Media Relations
Email: Send Email
Country: United Kingdom
Website: stjamess.org

Energy Tech Leader Zendure selected for UNESCO World Engineering Day 2025 Campaign

• The year-long initiative, launched on March 4, 2025, at UNESCO Headquarters in Paris, aims to showcase the critical role of engineering in achieving global sustainability goals.

London, UK – Mar 7, 2025 – Zendure, a leading innovator in solar energy technology, has been named an official partner for UNESCO World Engineering Day for Sustainable Development (WED) 2025.

World Engineering Day, an internationally recognized day proclaimed by UNESCO General Conference and open to everyone, is jointly operated by UNESCO and the World Federation for Engineering Organizations (WFEO). The WFEO represents over 30 million engineers across approximately 100 countries. The WED campaign serves as a global platform to celebrate engineering achievements, promote engineering careers, and raise awareness of the profession’s vital contributions to a sustainable future.

The 2025 campaign, produced by WED’s official media partner and broadcaster, SJH Group, features a dedicated multimedia hub showcasing Zendure’s expertise and commitment to sustainable energy solutions on the official WED website: www.worldengineeringday.net.

As an official partner, Zendure’s participation will provide valuable insights and perspectives throughout the 12-month campaign. This initiative aims to engage governments, UN-affiliated organizations, policymakers, educators, and industry leaders in a global conversation about the importance of engineering in addressing pressing environmental and societal challenges.

The WED campaign is projected to reach over 100 million people worldwide. This year’s theme, “Shaping our sustainable future through engineering,” directly aligns with the United Nations’ 17 Sustainable Development Goals (SDGs), emphasizing engineering’s indispensable role in achieving these ambitious targets.

Bryan Liu, CEO at Zendure, says: “We are honoured to be selected as an official partner for UNESCO World Engineering Day 2025. This collaboration provides a powerful platform to demonstrate how innovative engineering, particularly in the renewable energy sector, is essential for building a sustainable future for all.”

Jacques de Mereuil, Executive Director of the WFEO, says: “We’re thrilled to be involved in launching this important international celebration and campaign at UNESCO’s global headquarters in Paris. Zendure’s expertise in solar power makes them a valuable partner in highlighting the crucial role of engineering in creating a sustainable future.”

To view Zendure’s WED content, go to https://worldengineeringday.net/partner-stories/zendure/.

Notes to editor:

The WED 2025 launch, campaign and related content are live on www.worldengineeringday.net.

For further information about WED 2025 please email publishing@stjamess.org.

For further information about Zendure please email de.marketing@zendure.com

Media Contact
Company Name: St James’s House
Contact Person: Media Relations
Email: Send Email
Country: United Kingdom
Website: stjamess.org